PEP-Therapy Raises €1.3 Million in Seed Capital

PARIS--PEP-Therapy, a biotechnology company developing targeted therapies for cancer treatments, has raised €1.3 million in initial funding. This sum, invested by the Quadrivium 1 seed fund and a business angel, Dr Bernard Majoie, will enable PEP-Therapy to undertake regulatory development of its first therapeutic product, associated with a predictive biomarker for foreseeing the effectiveness of the treatment. The product relies on the innovative technology of bi-functional peptides, which penetrate cells and then specifically block pathological mechanisms, without affecting normal physiological mechanisms.

These funds were provided by the Quadrivium 1 seed fund, managed by Seventure Partners, for €1 million, supplemented by a personal investment of €300,000 from Dr Bernard Majoie, former Chairman and CEO of Laboratoires Fournier and Founding Chairman of Fondation Fournier-Majoie pour l'Innovation (FFMI).

Antoine Prestat, CEO of PEP-Therapy, welcomed this important new phase in the company's development. "Our first targeted therapy has convincing proofs of concept in pre-clinical models that are highly representative of the tumours seen in humans. The targeted cancers have significant clinical needs. This funding will allow us to carry out regulatory toxicity studies, the final phase before clinical trials."

"PEP-Therapy's product has an additional competitive advantage: it is combined with predictive biomarkers which will help identify patients likely to respond to treatment. This fits well with the experience in companion diagnostics gained by FFMI, and meets a currently increasing demand for personalised medicine", added Dr Bernard Majoie.

Philippe Tramoy, Investment Director at the Quadrivium 1 seed fund at Seventure Partners, said: "Trials of the first product associated with its biomarkers, developed by PEP-Therapy and its leading research and clinical partners*, will rapidly enable the company to demonstrate the clinical effectiveness of this new bi-functional peptide approach, in indications where the clinical need is substantial."

PEP-Therapy has a portfolio of targeted therapies based on the same innovative approach. "It is a cell-penetrating and interfering peptide (CP&IP) technology developed at Université Pierre et Marie Curie, Inserm and Institut Curie, Paris. With this financial support, PEP-Therapy is taking a new step forward, giving itself the resources required to scale up the promising development of its targeted treatments," welcomed Antoine Prestat.

  • Didier Decaudin, MD, PhD, Institut Curie, Department of Medical Oncology; Head of the Laboratory of Preclinical Investigation, Translational Research Department

  • Fariba Némati, PhD, Institut Curie, Laboratory of Preclinical Investigation

  • Angelita Rebollo, PhD, CIMI-Paris, Université Pierre et Marie Curie, CHU Pitié Salpêtrière

About PEP-Therapy

www.pep-therapy.com

About Seventure Partners

http://www.seventure.fr/en

About Quadrivium 1 Seed Fund

http://www.seventure.fr/en/our-institutional-funds

About Bernard Majoie

http://www.fournier-majoie.org/fr/apropos/organisation

Contact:

PEP-Therapy: Antoine Prestat, CEO – [email protected] – +33(0)1 44 27 81 90

 

Suggested Articles

Regeneron's latest cholesterol fighter cut "bad" cholesterol in half for patients with a rare genetic disorder, including in hard-to-treat…

J&J plans to have a vaccine in the clinic by September and win emergency use authorization early next year.

The biotech is pausing enrollment in some infectious and rare disease trials while continuing to try to add patients to its cancer studies.